Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Neuropilin-2 functions as a coinhibitory receptor to regulate antigen-induced inflammation and allograft rejection
Johannes Wedel, … , Diane R. Bielenberg, David M. Briscoe
Johannes Wedel, … , Diane R. Bielenberg, David M. Briscoe
Published July 1, 2025
Citation Information: J Clin Invest. 2025;135(13):e172218. https://doi.org/10.1172/JCI172218.
View: Text | PDF
Research Article Immunology

Neuropilin-2 functions as a coinhibitory receptor to regulate antigen-induced inflammation and allograft rejection

  • Text
  • PDF
Abstract

Coinhibitory receptors function as central modulators of the immune response to resolve T effector activation and/or to sustain immune homeostasis. Here, using humanized SCID mice, we found that neuropilin–2 (NRP2) is inducible on late effector and exhausted subsets of human CD4+ T cells and that it is coexpressed with established coinhibitory molecules including PD-1, CTLA4, TIGIT, LAG3, and TIM3. In murine models, we also found that NRP2 is expressed on effector memory CD4+ T cells with an exhausted phenotype and that it functions as a key coinhibitory molecule. Knockout (KO) of NRP2 resulted in hyperactive CD4+ T cell responses and enhanced inflammation in delayed-type hypersensitivity and transplantation models. After cardiac transplantation, allograft rejection and graft failure were accelerated in global as well as CD4+ T cell–specific KO recipients, and enhanced alloimmunity was dependent on NRP2 expression on CD4+ T effectors but not on CD4+Foxp3+ Tregs. Also, KO Tregs were found to be as efficient as WT cells in the suppression of effector responses in vitro and in vivo. These collective findings identify NRP2 as a potentially novel coinhibitory receptor and demonstrate that its expression on CD4+ T effector cells is of great functional importance in immunity.

Authors

Johannes Wedel, Nora Kochupurakkal, Sek Won Kong, Sayantan Bose, Ji-Won Lee, Madeline Maslyar, Bayan Alsairafi, Kayla MacLeod, Kaifeng Liu, Hengcheng Zhang, Masaki Komatsu, Hironao Nakayama, Diane R. Bielenberg, David M. Briscoe

×

Figure 5

KO of NRP2 within CD4+ T cells increases proinflammatory responses in vitro and in vivo.

Options: View larger image (or click on image) Download as PowerPoint
KO of NRP2 within CD4+ T cells increases proinflammatory responses in vi...
(A–C) CD4+ T cells isolated from WT, heterozygous NRP2-KO (NRP2+/–) and homozygous NRP2-KO (NRP2–/–) mice were stimulated with increasing concentrations of plate-bound anti-CD3. (A) Proliferation as evaluated by 3H-thymidine incorporation after 72 hours (mean cpm ± SD from triplicate conditions; 1-way ANOVA, **P < 0.01, ***P < 0.001 versus WT; representative of 3 independent experiments). (B) Cytokine concentrations in coculture supernatants from the experiments in A (1 μg/mL anti-CD3) measured by multiplex-analyte profiling. Heatmap represents mean cytokine concentrations of duplicate conditions (2 independent experiments). (C) IFN-γ and IL-2 production as assessed by ELISPOT (mean spots ± SD of triplicate condition; 1-way ANOVA, NS not significant, *P < 0.05, **P < 0.01, ***P < 0.001 versus WT; representative of 3 independent experiments). (D–H) WT and ΔNRP2-CD4-KO mice were immunized s.c. with NP-KLH (50 μg) in CFA, boosted after 7 days with NP-KLH (50 μg) in incomplete Freund’s adjuvant (IFA), and T cell and B cell responses were analyzed after an additional 7 days. (E) IFN-γ production (by ELISPOT) after restimulation of primed CD4+ T cells to KLH. Graphs represent mean spots per well ± SD from NRP2lox/lox (n = 6) and ΔNRP2-CD4 (n = 5) mice (Kruskal-Wallis test). (F) NP-specific IgG production in B cells by ELISPOT. Graphs represent mean spots per well ± SD from NRP2lox/lox (n = 4) and ΔNRP2-CD4 (n = 5) mice (Kruskal-Wallis test). (G) Phenotype of splenic CD4+ T cell subsets. Representative dot plots (top panels) and bar graphs depicting differences between NRP2lox/lox (n = 6) and ΔNRP2-CD4 (n = 5) mice (bottom panels; mean ± SD; unpaired t test). (H) Proliferation (BrdU incorporation) of CD4+CD44hiCD62Llo T effector/memory cells. Representative dot plots (top panels) and graphs depicting differences between NRP2lox/lox (n = 6) and ΔNRP2-CD4 (n = 5) mice (bottom panels; mean ± SD; unpaired t test). (I and J) WT, NRP2–/–, and ΔNRP2-CD4-KO mice were sensitized to oxazolone and challenged by application to the right ear in a standard DTH model; vehicle application to the left ear served as control. (I) Differences in thickness between right (challenge) and left (control) ears were measured daily (Δμm; 1-way ANOVA, **P < 0.01, ***P < 0.001 vs. WT). (J) H&E staining of challenged ears harvested on day 4 after challenge (representative of n = 3/condition).

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts